Biocept (Biocept) Growth Rank : 0 (As of May. 16, 2024)

View and export this data going back to 2014. Start your Free Trial

What is Biocept Growth Rank?

Biocept has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Biocept Growth Rank Related Terms

Thank you for viewing the detailed overview of Biocept's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Biocept (Biocept) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Biocept Inc (OTCPK:BIOCQ) » Definitions » Growth Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

9955 Mesa Rim Road, San Diego, CA, USA, 92121

Website

https://www.biocept.com

Biocept Inc develops and commercializes molecular diagnostic assays that provide physicians with clinically actionable information for treating and monitoring patients diagnosed with a variety of cancers. In addition to its portfolio of blood-based liquid biopsy assays, Biocept has developed the CNSide cerebrospinal fluid assay that detects cancer that has metastasized to the central nervous system. Biocept's patented Target Selector technology captures and quantitatively analyzes CSF tumor cells for tumor-associated molecular markers, using technology first developed for use in blood. It is also leveraging its molecular diagnostic capabilities to offer nationwide COVID-19 RT-PCR testing to support public health efforts during this unprecedented pandemic.

Executives

Robert Walsh	officer: VP, Controller	9955 MESA RIM ROAD, SAN DIEGO CA 92121
Quyen Thi Dao-haddock	director	C/O: PRESIDIO PROPERTY TRUST, INC., 1282 PACIFIC OAKS PLACE, ESCONDIDO CA 92029
Philippe Marchand	officer: Chief Operations Officer	C/O BIOCEPT, INC., 9955 MESA RIM ROAD, SAN DIEGO CA 92121
Darrell Taylor	officer: Sr. V.P., General Counsel	C/O BIOCEPT, INC., 9955 MESA RIM ROAD, SAN DIEGO CA 92121
David F Hale	director, officer: EXECUTIVE CHAIRMAN	1042-B NORTH EL CAMINO REAL, SUITE 430, ENCINITAS CA 92024
Antonino Morales	director	C/O BICOCEPT, INC., 9955 MESA RIM ROAD, SAN DIEGO CA 92121
Linda M Rubinstein	director	25861 INDUSTRIAL BLVD, HAYWARD CA 94545
Samuel D Riccitelli	director	2850 FRONTIER DR., WARSAW IN 46582
Michael C Dugan	officer: Chief Med Off & Med. Director	2211 MICHIGAN AVE, SANTA MONICA CA 90404-3900
Dunn Cory	officer: Sr. VP Corp. Development	C/O BIOCEPT, INC., 5810 NANCY RIDGE DR., # 150, SAN DIEGO CA 92121
Edwin Hendrick	officer: SVP, Chief Commercial Officer	2010 MAIN STREET, SUITE 600, IRVINE CA 92614
Michael J Terry	officer: Sr VP Comm. Operations
Marsha Alpert Chandler	director	7863 ENTRADA ANGELICA, SAN DIEGO CA 92127
Michael W. Nall	director, officer: CEO AND PRESIDENT	4 WOODHAVEN DRIVE, LAGUNA NIGUEL CA 92677
Timothy Kennedy	officer: CFO, Sr V.P. Operations & Sec.	5810 NANCY RIDGE DRIVE, SUITE 150, SAN DIEGO CA 92121